Key Points
- Insider sale: Illumina SVP Patricia Leckman sold 2,370 shares on February 18 at an average price of $116.18 for proceeds of $275,346.60, cutting her stake by 12.68% to 16,321 shares, per an SEC filing.
- Company performance and outlook: Illumina beat quarterly estimates with $1.35 EPS (vs. $1.26 est.) and $1.16B revenue, set FY2026 guidance of 5.050–5.200 EPS, trades around $120 with a $18.36B market cap, and carries a consensus "Hold" rating with a $127.94 price target.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) SVP Patricia Leckman sold 2,370 shares of the company's stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company's stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Illumina Trading Up 3.1%
NASDAQ ILMN opened at $120.09 on Thursday. The stock's 50-day simple moving average is $136.48 and its two-hundred day simple moving average is $116.92. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $18.36 billion, a price-to-earnings ratio of 22.03, a PEG ratio of 2.23 and a beta of 1.45.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.09. The firm had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.10 billion. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The company's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.95 EPS. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. Research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the 4th quarter worth approximately $25,000. Board of the Pension Protection Fund acquired a new stake in shares of Illumina during the fourth quarter worth about $26,000. Creative Capital Management Investments LLC grew its holdings in shares of Illumina by 160.0% during the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock worth $26,000 after buying an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in Illumina in the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in Illumina during the 4th quarter valued at approximately $26,000. Hedge funds and other institutional investors own 89.42% of the company's stock.
Analysts Set New Price Targets
ILMN has been the subject of a number of research analyst reports. Guggenheim raised their price target on Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Robert W. Baird set a $137.00 price target on shares of Illumina in a research report on Friday, February 6th. TD Cowen restated a "hold" rating on shares of Illumina in a report on Wednesday, January 7th. Barclays lifted their price target on Illumina from $100.00 to $110.00 and gave the company an "underweight" rating in a research report on Monday, December 15th. Finally, UBS Group reissued a "neutral" rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $127.94.
Get Our Latest Research Report on Illumina
Illumina Company Profile
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
